Taking HRT 'reduces risk of cardiovascular death'

HRT appears to reduce the risk of cardiovascular death, say US researchers in findings that contradict the controversial results of the Women's Health Initiative (WHI) study.

The likelihood of a major cardiovascular event was 33 per cent lower in women taking HRT after a natural menopause than those who took no HRT.

In 2000, the value of HRT was brought into question by the WHI study, which was terminated early after women were found to have an increased risk of heart disease, stroke and breast cancer after taking HRT.

Since the findings were published, the consensus has been to prescribe HRT only for a short time. But now data presented at the American Heart Association scientific sessions in Orlando, Florida, suggest that, rather than creating cardiovascular risk, HRT may prevent it.

Findings come from the Women's Ischaemia Syndrome Evaluation (WISE) study, that began in the mid-1990s before the concerns over HRT safety.

A cohort of 654 postmenopausal women, aged an average of 62, taking part in the WISE study were assessed for the latest research.

Overall, 42 per cent had obstructive coronary artery disease (CAD), defined as 50 per cent or more stenosis of at least one coronary vessel.

Among them, 23 per cent had had a major cardiovascular event. But HRT was also associated with a 33 per cent lower likelihood of major cardiovascular event, researchers say.

Analysis also showed that among the 520 women who underwent a natural menopause, over 40 per cent of those taking no HRT had CAD.

In comparison, around 10 per cent of those who had started taking HRT before the age of 45 developed CAD.

CAD was also less prevalent among those who started HRT after 45, but 20-25 per cent still had this diagnosis. The researchers did not identify if any one HRT was involved with this association. But they did find that duration of HRT use had no influence over the effect.

No such patterns were seen among the surgical menopause group. Researchers said the results were 'not an advocation for HRT'.

rachel.liddle@haymarket.com

AHA scientific sessions 4-7 November 2007, Orlando, Florida

Comment below and tell us what you think 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

NHS Employers updates guidance for assessing COVID-19 risk in BAME staff

NHS Employers updates guidance for assessing COVID-19 risk in BAME staff

Updated guidance to help GP practices assess and mitigate the risk staff from black,...

PHE unable to confirm it will meet deadline for COVID-19 risk report

PHE unable to confirm it will meet deadline for COVID-19 risk report

Public Health England (PHE) has been unable to confirm if its report into how factors...

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have seen a significant drop in income due to COVID-19

More than half of GP locums have experienced a significant fall in their income during...

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

How a GP helped develop a protective shield to cover patients needing CPR in the pandemic

Wiltshire GP Dr Lydia Campbell-Hill explains how she helped create a mini isolation...

GP practices can now sign up to new online PPE portal

GP practices can now sign up to new online PPE portal

GP practices will be able to register with the DHSC's new online PPE portal, which...

Fully-qualified GP workforce fell by 712 over the past year

Fully-qualified GP workforce fell by 712 over the past year

The fully-qualified GP workforce in England fell by 2.5%, losing 712 full-time equivalent...